Avastin News and Research

RSS

Avastin is a biologic antibody designed to specifically bind to a protein called vascular endothelial growth factor (VEGF) that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the blood supply to a tumor by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. Avastin does not bind to receptors on normal or cancer cells. The tumor blood supply is thought to be critical to a tumor’s ability to grow and spread in the body (metastasize).

State roundup: Calif. expands uninsured access, gives adult day care reprieve

Nearly two years before the federal health reform law kicks in, 10 California counties have expanded medical coverage to more than 250,000 people who were previously uninsured, according to new state data.

22 Feb 2012

Shortage looming, drug maker agrees to release emergency supplies of kids' cancer drug

A shortage of a drug used to treat children's cancer seems to have been averted for a time as the Food and Drug Administration says it reached an agreement with the drug supplier to release emergency supplies. Elsewhere, rules sometimes force hospitals to throw away scarce drugs.

17 Feb 2012

Drugmaker warns that fake cancer drug is on the market

The Wall Street Journal reports that the manufacturer of Avastin says it has found counterfeit vials of the drug in the United States.

16 Feb 2012

Counterfeit anti-cancer drug Avastin raises concerns

The market is flooded with a counterfeit version of cancer drug Avastin worry doctors and patients. Injectable drugs have become increasingly attractive to counterfeiters, in part because they often fetch a higher price than regular pills.

15 Feb 2012

Ovarian cancer subtype may be susceptible to 'anti-angiogenic' drugs

Scientists at Dana-Farber Cancer Institute have identified a subtype of ovarian cancer able to build its own blood vessels, suggesting that such tumors might be especially susceptible to "anti-angiogenic" drugs that block blood vessel formation.

15 Feb 2012

Researchers discover function and expression of CD97 in malignant gliomas

Researchers at Virginia Commonwealth University Medical Center's VCU Massey Cancer Center and Harold F. Young Neurosurgical Center and Old Dominion University have discovered that suppression of Wilms tumor 1 protein (WT1) results in downregulation of CD97 gene expression in three glioblastoma cell lines and reduces the characteristic invasiveness exhibited by glial tumor cells.

8 Feb 2012

Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-standard treatment

Roche/Genentech/Chugai's pertuzumab plus trastuzumab (Roche/Genentech/Chugai's Herceptin) and docetaxel (Sanofi's Taxotere, generics) will become Decision Resources' proprietary clinical gold-standard treatment for metastatic first-line HER2-positive breast cancer in 2015.

3 Feb 2012

Circadian's VGX-100 human antibody improves corneal graft survival

Circadian Technologies Limited announced today the publication of data in the scientific journal, Investigative Ophthalmology & Visual Science (IOVS), showing that VEGF-C expression is markedly up-regulated in corneal graft rejection.

30 Jan 2012

Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours

Circadian Technologies Limited announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre.

9 Jan 2012

Celldex begins rindopepimut and Avastin Phase 2 combination trial in EGFRvIII-positive GB

Celldex Therapeutics, Inc. today announced that patient screening has initiated in a Phase 2 trial of rindopepimut in combination with Avastin in patients with recurrent epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, called the "ReACT Study."

5 Jan 2012

Avastin fails to live up to expectations for extending survival in ovarian cancer

Cancer drug Avastin has been found to add about four months to the time it takes for the cancer to worsen for women with advanced cases of ovarian cancer says a new report. However it may not extend survival significantly.

29 Dec 2011

GOG targeted therapy phase 3 clinical trial delays progression of advanced ovarian cancer

Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer.

29 Dec 2011

Bevacizumab delays disease progression in ovarian cancer

Treating ovarian cancer with the drug bevacizumab ("Avastin") delays the disease and may also improve survival, show the results of an international clinical trial co-led by Drs. Amit Oza of the Princess Margaret Cancer Program, University Health Network and Timothy Perren, St James's Institute of Oncology, Leeds, UK.

29 Dec 2011

Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma

Celldex Therapeutics, Inc. today announced that it has launched a pivotal, randomized, double-blind, controlled Phase 3 trial of rindopepimut in patients with surgically resected epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, the "ACT IV Study."

1 Dec 2011

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Idera Pharmaceuticals, Inc. today announced that it has regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as part of an agreed-upon termination of its oncology collaboration with Merck KGaA, Darmstadt, Germany.

1 Dec 2011

Defending Washington's basic health plan; Questioning Wisconsin's proposed health care cuts

The Basic Health program has played an important role in extending the safety net to provide coverage to many low-income people who can't afford to purchase coverage on their own and don't qualify for Medicaid. It's much easier to retain an infrastructure than to build a new one from scratch. Simply put, leaving people without health insurance lengthens the recession and imposes costs on us all.

23 Nov 2011

Medicare will still cover Avastin for breast cancer, despite revocation of FDA approval

The FDA announced that Avastin, while still approved for other cancers, is more harmful than helpful to breast cancer patients.

22 Nov 2011

Breast cancer drug Avastin loses FDA support

According to a Food and Drug Administration (FDA) announcement last Friday, the cancer drug Avastin should not be used to treat breast cancer that has spread to other organs because it doesn't help patients enough to justify its risky side effects.

21 Nov 2011

Viewpoints: Finding savings in Medicare; The Avastin saga; Changes in health care business

There is no way to wrestle down the deficit without reining in Medicare costs. Ensuring that the program provides quality health care coverage to millions of older and disabled Americans is essential. These goals are not incompatible, but they require a judicious approach to policy making that is depressingly absent in Washington.

21 Nov 2011

Avastin drug not safe and effective for breast cancer patients: FDA Commissioner

FDA Commissioner Margaret A. Hamburg, M.D., said today she is revoking the agency's approval of the breast cancer indication for Avastin (bevacizumab) after concluding that the drug has not been shown to be safe and effective for that use.

19 Nov 2011

Avastin News and Research

Further Reading

State roundup: Calif. expands uninsured access, gives adult day care reprieve

Shortage looming, drug maker agrees to release emergency supplies of kids' cancer drug

Drugmaker warns that fake cancer drug is on the market

Counterfeit anti-cancer drug Avastin raises concerns

Ovarian cancer subtype may be susceptible to 'anti-angiogenic' drugs

Researchers discover function and expression of CD97 in malignant gliomas

Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-standard treatment

Circadian's VGX-100 human antibody improves corneal graft survival

Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours

Celldex begins rindopepimut and Avastin Phase 2 combination trial in EGFRvIII-positive GB

Avastin fails to live up to expectations for extending survival in ovarian cancer

GOG targeted therapy phase 3 clinical trial delays progression of advanced ovarian cancer

Bevacizumab delays disease progression in ovarian cancer

Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Defending Washington's basic health plan; Questioning Wisconsin's proposed health care cuts

Medicare will still cover Avastin for breast cancer, despite revocation of FDA approval

Breast cancer drug Avastin loses FDA support

Viewpoints: Finding savings in Medicare; The Avastin saga; Changes in health care business

Avastin drug not safe and effective for breast cancer patients: FDA Commissioner

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News